Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate Regimen and Its Effect on Liver Steatosis Assessed by Fibroscan.

IF 3.8 3区医学 Q2 VIROLOGY

Viruses-Basel Pub Date : 2025-03-19 DOI:10.3390/v17030440

Marcello Trizzino, Roberta Gaudiano, Dalila Mimì Arena, Luca Pipitò, Claudia Gioè, Antonio Cascio

{"title":"Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate Regimen and Its Effect on Liver Steatosis Assessed by Fibroscan.","authors":"Marcello Trizzino, Roberta Gaudiano, Dalila Mimì Arena, Luca Pipitò, Claudia Gioè, Antonio Cascio","doi":"10.3390/v17030440","DOIUrl":null,"url":null,"abstract":"Background: Antiretroviral therapy has transformed HIV infection from a fatal disease to a chronic and manageable condition, but increasing health issues beyond acquired immunodeficiency syndrome, such as metabolic, liver, and cardiovascular diseases, have been observed. Furthermore, the increasing prevalence of HIV strains resistant to older antiretroviral regimens has necessitated a re-evaluation of treatment strategies.Methods: We performed a retrospective, observational study to evaluate the long-term outcomes of an antiretroviral switch from a non-nucleoside reverse transcriptase inhibitor-based to bictegravir-based regimen; this study aimed to assess the impact of this antiretroviral switch on treatment adherence, the safety profile, and virologic outcomes. The secondary objectives were to analyze the changes in lipid, kidney function, liver function, and anthropometric parameters after switching.Results: A total of 25 patients were included in this analysis; virologic suppression was maintained over time, with 100% of patients demonstrating undetectable viral loads at 6, 12, 24, and 36 months. In parallel, a significant increase in CD4+ cell count was observed after switching. No significant differences were observed compared to the previous therapy regarding anthropometric parameters or laboratory parameters. However, a significant reduction in liver steatosis, as assessed by Fibroscan, was observed.Conclusions: bictegravir-based regimens are a valid therapeutic option for people living with HIV, particularly for those with metabolic comorbidities.","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"17 3","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11945801/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Viruses-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/v17030440","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Antiretroviral therapy has transformed HIV infection from a fatal disease to a chronic and manageable condition, but increasing health issues beyond acquired immunodeficiency syndrome, such as metabolic, liver, and cardiovascular diseases, have been observed. Furthermore, the increasing prevalence of HIV strains resistant to older antiretroviral regimens has necessitated a re-evaluation of treatment strategies.

Methods: We performed a retrospective, observational study to evaluate the long-term outcomes of an antiretroviral switch from a non-nucleoside reverse transcriptase inhibitor-based to bictegravir-based regimen; this study aimed to assess the impact of this antiretroviral switch on treatment adherence, the safety profile, and virologic outcomes. The secondary objectives were to analyze the changes in lipid, kidney function, liver function, and anthropometric parameters after switching.

Results: A total of 25 patients were included in this analysis; virologic suppression was maintained over time, with 100% of patients demonstrating undetectable viral loads at 6, 12, 24, and 36 months. In parallel, a significant increase in CD4+ cell count was observed after switching. No significant differences were observed compared to the previous therapy regarding anthropometric parameters or laboratory parameters. However, a significant reduction in liver steatosis, as assessed by Fibroscan, was observed.

Conclusions: bictegravir-based regimens are a valid therapeutic option for people living with HIV, particularly for those with metabolic comorbidities.

查看原文本刊更多论文

切换到比替格拉韦/恩曲他滨/富马酸替诺福韦阿拉胺方案及其对肝脂肪变性的影响

背景：抗逆转录病毒治疗已将艾滋病毒感染从一种致命疾病转变为一种慢性和可控制的疾病，但已观察到除获得性免疫缺陷综合征外，代谢、肝脏和心血管疾病等健康问题越来越多。此外，对较旧的抗逆转录病毒治疗方案有耐药性的艾滋病毒株的流行率日益增加，因此有必要重新评估治疗策略。方法：我们进行了一项回顾性观察性研究，以评估从基于非核苷类逆转录酶抑制剂到基于比替格拉韦方案的抗逆转录病毒转换的长期结果；本研究旨在评估这种抗逆转录病毒转换对治疗依从性、安全性和病毒学结果的影响。次要目的是分析转换后血脂、肾功能、肝功能和人体测量参数的变化。结果：本分析共纳入25例患者；随着时间的推移，病毒学抑制得以维持，100%的患者在6、12、24和36个月时显示无法检测到病毒载量。同时，转换后观察到CD4+细胞计数显著增加。与以前的治疗相比，在人体测量参数或实验室参数方面没有观察到显著差异。然而，根据纤维扫描的评估，观察到肝脂肪变性的显著减少。结论：以比替克韦为基础的治疗方案是艾滋病毒感染者的有效治疗选择，特别是对于那些有代谢合并症的人。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Viruses-Basel VIROLOGY-

CiteScore

7.30

自引率

12.80%

发文量

2445

审稿时长

1 months

期刊介绍： Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the ''News and Views'' section. Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.